Other News To Note
Wednesday, May 30, 2012
Bionomics Ltd., of Adelaide, Australia, said it launched a Phase I/II trial of BNC105 in women with ovarian cancer. Up to 134 patients are expected to be enrolled in the study, which is designed to test the vascular-disrupting agent in combination with current standard therapies carboplatin and gemcitabine.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.